Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
== Medical uses == Ertapenem is indicated for the treatment of intra-abdominal infections, community-acquired pneumonia, pelvic infections, and diabetic foot infections, with bacteria that are susceptible to this drug, or expected to be so. It can also be used to prevent infections after colorectal surgery. In the United States it is also indicated for the treatment of complicated urinary tract infections including pyelonephritis. It is a potential effective alternative treatment for ceftriaxone-resistant gonorrhoea. It is given as an intravenous infusion or intramuscular injection. The drug is not approved for children under three months of age.
An improved reaction developed by chemist Karl Barry Sharpless involves the copper (I) catalyst, which couples azide with terminal alkyne that only give 1,4 substituted 1,2,3 triazoles in high yields (shown below in Figure 11). The mechanistic study suggests a stepwise reaction. The Cu (I) first couples with acetylenes, and then it reacts with azide to generate a six-membered intermediate. The process is very robust that it occurs at pH ranging from 4 to 12, and copper (II) sulfate is often used as a catalyst in the presence of a reducing agent.
Le Havre Octeville Airport which is located 5 km (3 mi) north of Le Havre at the town of Octeville-sur-Mer and managed by CODAH. The airport does not have any scheduled services to or from Le Havre at this time. Currently, air travel is served by the nearest Caen–Carpiquet Airport which is located approximately 54 km away from Le Havre. The main destination is the Transport hub of Lyon. Many holiday destinations are offered each year (Tunisia, Balearic Islands, Portugal, Greece, Bulgaria, etc.) through local travel agencies that charter aircraft. There is also the Flying club Jean Maridor at the airport. The Channel maritime links with Portsmouth in southern England with P&O Ferries ended on 30 September 2005 to be taken over by LD Lines who had changed the configuration. Two services to Portsmouth are provided daily from the Terminal de la Citadelle until ceasing operations in 2014, the route has since been taken over by Brittany Ferries. It will cease in September 2026. The link to Ireland was moved to the port of Cherbourg. Crossing times to Portsmouth vary from five hours and thirty minutes to eight hours. Popular alternative routes going to areas close to Le Havre include Newhaven to Dieppe, and Poole to Cherbourg.
Sources: en.wikipedia.org
Cholesterol is the principal sterol of all animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Cholesterol is biosynthesized by all animal cells and is an essential structural and signaling component of animal cell membranes. In vertebrates, hepatic cells typically produce the greatest amounts of it. In the brain, astrocytes produce cholesterol and transport it to neurons. It is absent among prokaryotes (bacteria and archaea), although there are some exceptions, such as Mycoplasma, which require cholesterol for growth. Cholesterol also serves as a precursor for the biosynthesis of steroid hormones, bile acid, and vitamin D. Elevated levels of cholesterol in the blood, especially when bound to low-density lipoprotein (LDL, often referred to as "bad cholesterol"), may increase the risk of cardiovascular disease. François Poulletier de la Salle first identified cholesterol in solid form in gallstones in 1769. In 1815, chemist Michel Eugène Chevreul named the compound "cholesterine".
In May 2025, Moore signed into law a bill that would establish a $25 million grant fund to expand abortion access for uninsured or underinsured individuals, funded a $1 surcharge on insurance plans sold under the Affordable Care Act. The law made Maryland become the first state to use these funds for this purpose. The program was blocked from going into effect by federal health officials in January 2026, who said the program "exceeds permissible use" of the fees collected by the Affordable Care Act. In May 2026, Moore signed into law a bill requiring hospitals to perform abortions in emergency medical situations.
=== International hospitals and facilities === Internationally, UPMC operates a transplant hospital in Italy (ISMETT), two hospitals and two cancer centers in Ireland, a cancer center in Rome and previously helped to establish an emergency medical system in Qatar. UPMC also implemented information technology solutions and assisting with the development of cancer centers in the United Kingdom, is providing consultation services and developing a network of co-managed hospitals in China, and, with the University of Pittsburgh School of Medicine, implemented a U.S.-style resident training program in Japan. UPMC is also a partner with the University of Pittsburgh and the governments of Italy and the region of Sicily in Fondazione Ri.Med, which is building a €210 million Biomedical Research and Biotechnology Center in Carini near Palermo. In June 2019, UPMC signed a deal with the Wanda Group to develop and operate five private hospitals in major Chinese cities. The first hospital, the Chengdu Wanda-UPMC International Hospital, is expected to open in 2022.
Sources: en.wikipedia.org
== Dominican studies == Peukert was fluent in Spanish, and was very interested in the history of Latin America, especially the Dominican Republic, which he spent much of the late 1980s visiting. As the name Detlev is hard for Spanish speakers to pronounce, Peukert took to calling himself "Julio" Peukert. Peukert was interested in youth policy in the Dominican Republic and spent much time in the barrios (slums) of Santo Domingo working as a volunteer helping poor teenagers. In 1986, Peuket published a book in Spanish Anhelo de Dependencia Las Ofertas de Anexion de la Republica Dominicana a los Estados Unidos en siglo XIX about the debate concerning American plans to annex the Dominican Republic in the 19th century. Always a politically engaged historian, Peukert engaged in city planning for Santo Domingo and criticized the Dominican government for not doing more to help with the problems of poverty. At the time of his death, Peukert had begun writing a biography of the Dominican dictator General Rafael Trujillo.
The Singaporean military, one of the smallest but most technologically advanced in Southeast Asia, consists of the Army, the Navy, the Air Force and the Digital and Intelligence Service. It is seen as the guarantor of the country's independence, translating into Singapore culture, involving all citizens in the country's defence. The government spent 2.7% of the country's GDP on the military in 2024, the highest in the region. After its independence, Singapore had only two infantry regiments commanded by British officers. Considered too small to provide effective security for the new country, the development of its military forces became a priority. In addition, in October 1971, Britain pulled its military out of Singapore, leaving behind only a small British, Australian and New Zealand force as a token military presence. A great deal of initial support came from Israel, a country unrecognised by Singapore's neighbouring Muslim-majority nations of Malaysia and Indonesia. The Israel Defense Forces (IDF) commanders were tasked by the Singapore Government to create the Singapore Armed Forces (SAF) from scratch, and Israeli instructors were brought in to train Singaporean soldiers. Military courses were conducted according to the IDF's format, and Singapore adopted a system of conscription and reserve service based on the Israeli model. Singapore still maintains strong security ties with Israel and is one of the biggest buyers of Israeli arms and weapons systems, with one recent example being the MATADOR anti-tank weapon.
== Research == The exact mechanism for this protein is currently not known, but efforts continue to isolate activated protein C mutants that lack anticoagulant properties for potential therapeutic use.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.